Semaglutide Generics
10 articles on Semaglutide Generics, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Slimming Drugs Boom Sparks Misuse Concerns in India
The surge in GLP-1 weight-loss injections like semaglutide in India, fueled by prices dropping up to 90%, is alarming doctors amid rising cosmetic misuse by young women. Social media and wedding pressures are pushing unsupervised use, risking serious side effects. Experts stress these are prescription therapies for obesity, not quick fixes.
5 min read
Inside India's GLP-1 Rush: Generics, Hype, Risks
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
5 min read
India's GLP-1 Opportunity: Startups Betting Big on Weight Loss
With semaglutide's patent expired in India, over 50 generic brands are flooding the market at competitive prices, fueling a five-fold GLP-1 expansion to ₹5,000 crore by 2030. Startups like HealthifyRx, VLCC, Sugarfit, and FITPASS are redefining weight loss with holistic programs combining drugs, coaching, and muscle preservation. Investors warn that only comprehensive care models will thrive amid rising competition.
6 min read
Ajanta Pharma, Sun Pharma Poised for GLP-1 Opportunity in India Market Shift
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
4 min read
Ozempic Goes Generic Worldwide, But Not in U.S. Until 2030
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
5 min read
India Steps Up Oversight on GLP-1 Drugs Over Improper Practices
India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.
4 min read
GLP-1 Rush: Pharma, Food Firms Eye Tie-Ups for India's Weight-Loss Boom
With Novo Nordisk's semaglutide patent expiring, Indian drugmakers like Sun Pharma and Dr Reddy's are rushing generics while partnering with food giants for muscle-preserving nutrition. This GLP-1 boom addresses 25-40% lean muscle loss in weight reduction. Learn how companies like Mankind and Amul are reshaping obesity care.
5 min read
Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide in India
Indian pharma leaders Sun Pharma, Dr Reddy's, and Glenmark have launched generic semaglutide injections in India, slashing costs compared to Ozempic and Wegovy after patent expiry. With weekly prices starting at Rs 325, these options make GLP-1 therapy accessible for type 2 diabetes and weight management. Zydus joins with more affordable brands, transforming treatment affordability.
5 min read
Low-Cost Semaglutide Generics Coming to India as Patent Expires
India's Semaglutide patent expires March 20, opening doors for low-cost generics from pharma giants like Zydus, Torrent, Sun Pharma, and Dr. Reddy's. With over 23% of women and 22% of men overweight per NFHS-5, and 45 crore adults projected obese by 2050, affordable options could reshape the fight against obesity and diabetes. Discover the price revolution and challenges ahead.
5 min read
India GLP-1 Weight-Loss Drug Market to Reach ₹5,000 Crore by 2030: CareEdge
India's GLP-1 and weight-loss drug market is set for explosive growth, expanding fivefold to ₹5,000 crore by 2030, according to CareEdge Ratings. Semaglutide's patent expiry will trigger sharp price cuts, boosting access amid surging demand from type 2 diabetes patients. However, generic makers face patent battles, manufacturing hurdles, and safety scrutiny.
5 min read